Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Prithviraj Bose et al.|New England Journal of Medicine|2019Cited by 502
Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemiaNitin Jain, William G. Wierda, Wei‐Ying Jen et al.|Blood|2025Cited by 3